Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

OU Health marked a significant breakthrough for Oklahoma in lung cancer treatment, becoming the first health care system in ...

These findings could pave the way for new treatment approaches for cancers driven by RAS mutations. Researchers at the ...

The WVU Cancer Institute at United Hospital Center (UHC) is offering CYTALUX® (pafolacianine), a groundbreaking imaging agent ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all ... Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy ...

In another triumph for AI in healthcare, researchers have developed a model that can spot bits of brain tumors that surgeons ...

Not only that, but the AI can return these results within 10 seconds, making it a potentially powerful aid to surgeons in the ...